Others
- Page Path
-
- HOME
- ARTICLE CATEGORY
- Others
- 22
- Transjugular Intrahepatic Portosystemic Shunt ; Results in cirrhotic patients due to hepatitis viruses
- Jae Hyung Park , Yong Joo Kim , Jin Wook Chung , Joon Koo Han
- Clin Mol Hepatol. 1995;1(1):92-98. Published online January 1, 1970
-
-
View: 2070 Download: 15
- 문맥압 항진증의 외과적 지견
- 김병로
- Clin Mol Hepatol. 1995;1(1):90-91. Published online January 1, 1970
-
-
View: 2062 Download: 13
- 식도 , 위 정맥류의 내시경적 치료
- 현진해, 문정섭
- Clin Mol Hepatol. 1995;1(1):82-89. Published online January 1, 1970
-
-
View: 1896 Download: 13
- 문맥압 항진증 ; 내과적 치료의 최신 지견
- 정규원
- Clin Mol Hepatol. 1995;1(1):74-81. Published online January 1, 1970
-
-
View: 2044 Download: 13
- 문맥압 항진증의 병태생리
- 서동진
- Clin Mol Hepatol. 1995;1(1):68-73. Published online January 1, 1970
-
-
View: 2276 Download: 15
- 21
- 만성 마이러스성 간염에 대한 인터페론 치료의 부작용 및 문제점
- 이효석
- Clin Mol Hepatol. 1995;1(1):63-67. Published online January 1, 1970
-
-
View: 2790 Download: 77
- 만성 C형 간염에서 인터페론 치료
- 이창홍
- Clin Mol Hepatol. 1995;1(1):54-62. Published online January 1, 1970
-
-
View: 2472 Download: 29
- 만성 B형 간염에서 인터페론의 치료효과
- 유재영
- Clin Mol Hepatol. 1995;1(1):45-53. Published online January 1, 1970
-
-
View: 2401 Download: 29
- 간염바이러스와 인터페론의 상호 억제작용
- 이영석
- Clin Mol Hepatol. 1995;1(1):35-44. Published online January 1, 1970
-
-
View: 2219 Download: 23
- 만성간염에서 항바이러스제제의 치료효과
- 전재윤
- Clin Mol Hepatol. 1995;1(1):30-34. Published online January 1, 1970
-
-
View: 2798 Download: 21
- 만성 바이러스성 간염의 병태생리
- 손주현, 기춘석
- Clin Mol Hepatol. 1995;1(1):13-29. Published online January 1, 2000
-
-
View: 4205 Download: 256
- Reply to Correspondence
- Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B”
- Pin-Nan Cheng, Ming-Lung Yu
- Received April 5, 2024 Accepted April 9, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0228 [Epub ahead of print]
-
View: 537 Download: 24
- Reply to correspondence
- Reply to correspondence regarding “Evaluation of the histological scoring systems for autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”
- Atsumasa Komori
- Received April 9, 2024 Accepted April 10, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0242 [Epub ahead of print]
-
View: 593 Download: 16
- Correspondence
- Reply to: “Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization”
- Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu
- Received April 16, 2024 Accepted April 19, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0266 [Epub ahead of print]
-
View: 427 Download: 16
- Reply to Correspondence
- Complement proteins and liver diseases: A response to the correspondence
- Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
- Received April 30, 2024 Accepted April 30, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0320 [Epub ahead of print]
-
View: 477 Download: 36
- Correspondence
- Correspondence on Letter regarding “Liver Sinusoidal Endothelial Cell: An Important Yet Often Overlooked Player in the Liver Fibrosis”
- Jiaorong Qu, Le Wang, Xiaojiaoyang Li
- Received May 14, 2024 Accepted May 15, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0357 [Accepted]
-
View: 339 Download: 23
- Reply to Correspondence
- Reply to correspondence: “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
- Eileen Laurel Yoon, Dae Won Jun
- Received May 15, 2024 Accepted May 19, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0360 [Accepted]
-
View: 341 Download: 9
- Correspondence
- Reply to Unlocking the future: machine learning sheds light on prognostication for early-stage hepatocellular carcinoma
- Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
- Received May 16, 2024 Accepted May 19, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0365 [Accepted]
-
View: 332 Download: 11
- Correspondence on Editorial regarding “Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: a gateway to personalized medicine”
- Su Bin Lim, Hyo Jung Cho
- Received May 16, 2024 Accepted May 19, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0368 [Accepted]
-
View: 360 Download: 20
- Correspondence on editorial regarding “Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?”
- Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
- Received May 24, 2024 Accepted May 29, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0394 [Accepted]
-
View: 370 Download: 25
- Correspondence on Editorial regarding “Dynamic Assessment of Modified Quick Sequential Organ Failure Assessment in Acutely Deteriorated Patients with Chronic Liver Disease”
- Do Seon Song, Dong Joon Kim
- Received June 12, 2024 Accepted June 14, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0448 [Accepted]
-
View: 421 Download: 5
- Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era
- Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
- Received June 24, 2024 Accepted June 29, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0472 [Accepted]
-
View: 151 Download: 6
- Special Topic
- A new Korean nomenclature for steatotic liver disease: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
- Received June 26, 2024 Accepted June 30, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0467 [Epub ahead of print]
-
View: 160 Download: 26
- Correspondence
- The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid's mechanisms of action
- Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
- Received June 24, 2024 Accepted July 5, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0471 [Accepted]
-
View: 112 Download: 12
- Correspondence on Editorial regarding“Macrophage ATG16L1: potential candidate for MASH treatment”
- Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu
- Received June 24, 2024 Accepted July 5, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0470 [Accepted]
-
View: 146 Download: 13
- Correspondence on Editorial regarding “Class II Transactivator Restricts Viral Replication and Extends Its Effect to HBV”
- Mehrangiz Dezhbord, Kyun-Hwan Kim
- Received July 3, 2024 Accepted July 8, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0515 [Accepted]
-
View: 125 Download: 23
- Review Article
- Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
- Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
- Received April 28, 2024 Accepted July 10, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0315 [Accepted]
-
View: 213 Download: 24
- Reply to correspondence
- Response to: Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era
- Seren M. Gedallovich, Paul Y. Kwo
- Received July 10, 2024 Accepted July 11, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0546 [Accepted]
-
View: 96 Download: 3
- Reply to Correspondence
- Reply to correspondence regarding “Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV”
- Cho-Rong Lee, Sung-Gyoo Park
- Received July 16, 2024 Accepted July 17, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0572 [Accepted]
-
View: 10 Download: 2
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor14.0First decision
09 Days
Publication after acceptance
03 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2022-2024)
|
|||||||
